Myriad Genetics logo
Myriad Genetics MYGN
$ 3.58 -1.1%

Quarterly report 2026-Q1
added 05-06-2026

report update icon

Myriad Genetics Financial Statements 2011-2026 | MYGN

Annual Financial Statements Myriad Genetics

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008

Market Cap

409 M 973 M 1.8 B 1.74 B 2.21 B 1.49 B 2 B 2.97 B 1.62 B 2.17 B 2.4 B 2.78 B 2.43 B 2.19 B 1.91 B 1.72 B 3.45 B -

Shares

92.6 M 90.6 M 82.8 M 80.6 M 80 M 75.4 M 73.5 M 69.4 M 68.3 M 70 M 71.3 M 75.7 M 80.9 M 84.6 M 89.8 M 96.3 M 93.5 M -

Historical Prices

4.42 10.7 21.8 21.6 27.6 19.8 27.2 29.1 34.4 16.7 43.2 34.1 21 27.2 20.9 17.8 36.9 24.6

Net Income

-366 M -127 M -263 M -112 M -27.2 M -53.1 M 4.6 M 131 M 21.8 M 125 M 80.2 M 176 M 147 M 112 M 101 M 152 M 84.6 M -

Revenue

824 M 838 M 753 M 678 M 691 M 300 M 851 M 773 M 771 M 754 M 723 M 778 M 613 M 496 M 402 M 363 M 327 M -

Cost of Revenue

248 M 252 M 236 M 202 M - - - - 145 M 133 M 133 M 96.1 M 64.4 M 51.5 M 45.6 M 44.3 M 43.3 M -

Gross Profit

577 M 585 M 517 M 476 M - - - 595 M 600 M 596 M 576 M 669 M 534 M 431 M 355 M - - -

Operating Income

-387 M -124 M -257 M -141 M -190 M -87.8 M 7.6 M 122 M 44 M 153 M 134 M 274 M 228 M 180 M 158 M 135 M 126 M -

Interest Expense

800 K 1.1 M 2.9 M 3.2 M 6.6 M 5.8 M 12 M 3.2 M 6 M 300 K 200 K -2 M -200 K -407 K 1.87 M - - -

EBITDA

-334 M -62.3 M -196 M -87.9 M -128 M -52 M 80.6 M 112 M 97.7 M 194 M 159 M 288 M 237 M 189 M 165 M 142 M 136 M -

Operating Expenses

964 M 709 M 774 M 617 M - - - 538 M 551 M 430 M 442 M 395 M 306 M 251 M 198 M - - -

General and Administrative Expenses

257 M 276 M 284 M 248 M 538 M 260 M 556 M 467 M 476 M 359 M 366 M 327 M 252 M 208 M 170 M 161 M 139 M -

All numbers in USD currency

Quarterly Income Statement Myriad Genetics

2026-Q1 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

93.7 M 93.1 M 92.5 M 91.4 M 91.3 M 90.9 M 90.6 M 89.9 M 89.9 M 81.9 M 81.7 M 81.3 M 81.2 M 80.7 M 80.4 M 80.1 M 80 M 78.8 M 77.2 M 76 M 75.4 M 74.7 M 74.6 M 74.7 M 74.4 M 73.7 M 74.4 M 73.7 M 74.2 M 73 M 74.2 M 73 M 69.3 M 68.6 M 69.3 M 68.6 M 68.2 M 68.8 M 68.2 M 68.8 M 70.5 M 68.7 M 70.5 M 68.7 M 72.5 M 72.8 M 72.5 M 72.8 M 75.1 M 79.6 M 75.1 M 79.6 M 81.7 M 81.6 M 81.7 M 81.6 M 84.5 M 85.2 M 84.5 M 85.2 M

Net Income

-34.1 M -27.4 M -330 M -100 K - -22.1 M -36.7 M -26 M - -61.3 M -116 M -54.7 M - -35.1 M -14.1 M -20.5 M - 24.6 M -4.7 M -39.5 M -37.9 M -15.2 M -55.4 M -15.2 M -8.3 M -8.3 M -8.3 M -20.6 M 2.6 M 2.6 M 2.6 M -700 K 30.9 M 78.8 M 32.1 M 81.1 M 6.1 M -700 K 5.9 M -1.2 M 37.1 M 30.3 M 30.3 M 26.6 M 24 M 16 M 24 M 16 M 50.4 M 55.5 M 50.4 M 55.5 M 35 M 30.1 M 35 M 30.1 M 28.3 M 25.1 M 28.3 M 25.1 M

Revenue

200 M 206 M 213 M 196 M - 213 M 212 M 202 M - 192 M 184 M 181 M - 156 M 179 M 165 M - 167 M 189 M 173 M 155 M 145 M 93.2 M 145 M 195 M 186 M 195 M 186 M 217 M 202 M 217 M 194 M 194 M 190 M 384 M 197 M 196 M 178 M 196 M 178 M 193 M 184 M 193 M 184 M 184 M 169 M 184 M 169 M 204 M 202 M 204 M 202 M 149 M 133 M 149 M 133 M 123 M 110 M 123 M 110 M

Cost of Revenue

62.8 M 61.9 M 61.3 M 61.7 M - 63.5 M 64.4 M 64.6 M - 57.6 M 57.8 M 59.2 M - 50.4 M 49.7 M 48 M - - - - - - - - - - - - - - - 36.8 M 37.7 M 36.2 M 73.9 M 37.9 M 37.4 M 34.3 M 37.4 M 34.3 M 34.1 M 30.9 M 34.1 M 30.9 M 35.1 M 32.8 M 35 M 32.8 M 22.8 M 21.4 M 22.8 M 21.4 M 15.6 M 13.9 M 15.6 M 13.9 M 12.8 M 11.3 M 12.8 M 11.3 M

Gross Profit

138 M 144 M 152 M 134 M - 150 M 147 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-30.7 M -23.3 M -329 M -29 M - -20 M -36.5 M -27.9 M - -60.1 M -114 M -52.2 M - -45 M -17.8 M -25.6 M - -79.9 M -20.8 M -46.7 M -48.2 M -39.6 M -68.3 M -39.6 M -8.8 M -20.9 M -8.8 M -20.9 M 6.1 M 1.2 M 6.1 M 1.2 M 6.3 M 84 M 4.4 M 87.4 M 17.2 M 7.1 M 13.2 M 6.2 M 45.2 M 43.3 M 45.2 M 43.3 M 36.3 M 25.9 M 36.3 M 25.9 M 83 M 82.9 M 83 M 82.9 M 55.6 M 48.6 M 55.6 M 48.6 M 45.5 M 41.5 M 45.5 M 41.5 M

Interest Expense

- 400 K -100 K 100 K - -800 K -300 K 500 K - -700 K -2.4 M 500 K - 800 K 600 K 900 K - 1.1 M 2 M 3 M 2.9 M 2.9 M 3.1 M 2.9 M 2.5 M 2.9 M 2.5 M 2.9 M 3.4 M 2.2 M 3.4 M 2.2 M 700 K 900 K 700 K 900 K 2.6 M 700 K 2.6 M -2.5 M 100 K 100 K -300 K 100 K 1.5 M -100 K 1.51 M -98 K -185 K -439 K -185 K 923 K 14 K 1.24 M - - - - - 488 K

EBITDA

-18.2 M -18.5 M -324 M -14.6 M - -15.2 M -31.9 M -12.2 M - -56.7 M -111 M -32.8 M - -42.1 M -15 M -12.6 M - -30.4 M -3.9 M -28.3 M -48.2 M -21.9 M -50.6 M -21.9 M 9.4 M -2.7 M 27.6 M -2.7 M 24.1 M 19.5 M 24.1 M 19.5 M 19.4 M 97.2 M 17.5 M 101 M 30.1 M 16.3 M 26.2 M 15.4 M 52 M 50.1 M 52 M 50.1 M 42.3 M 31.9 M 42.4 M 31.9 M 85.4 M 85.3 M 85.4 M 85.3 M 57.8 M 50.8 M 60 M 48.9 M 45.7 M 43.6 M 49.9 M 43.6 M

Operating Expenses

168 M 167 M 481 M 163 M - 170 M 184 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

62.2 M 67.9 M 66.8 M 66.5 M - 69.2 M 72.1 M 141 M - 136 M 141 M 152 M - 130 M 127 M 111 M - 181 M 135 M 146 M 133 M 124 M 107 M 124 M 134 M 136 M 136 M 136 M 135 M 130 M 135 M 130 M 107 M 107 M 115 M 115 M 120 M 112 M 120 M 112 M 90.8 M 86.5 M 90.8 M 86.5 M 92.7 M 85.4 M 92.7 M 85.4 M 77.8 M 77.3 M 77.8 M 77.3 M 59.6 M 56.1 M 59.6 M 56.1 M 51 M 46.1 M 51 M 46.1 M

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements Myriad Genetics MYGN
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting Myriad Genetics plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Diagnostics research industry

Issuer Price % 24h Market Cap Country
Co-Diagnostics Co-Diagnostics
CODX
$ 1.29 -21.17 % $ 1.72 M usaUSA
Centogene N.V. Centogene N.V.
CNTG
- -6.23 % $ 30.6 M germanyGermany
Fulgent Genetics Fulgent Genetics
FLGT
$ 15.7 -3.03 % $ 475 M usaUSA
Agilent Technologies Agilent Technologies
A
$ 111.7 -1.38 % $ 34 B usaUSA
Castle Biosciences Castle Biosciences
CSTL
$ 19.13 1.32 % $ 555 M usaUSA
Akumin Akumin
AKU
- -17.87 % $ 25.9 M canadaCanada
Aspira Women's Health Aspira Women's Health
AWH
- -6.19 % $ 10.5 M usaUSA
Accelerate Diagnostics Accelerate Diagnostics
AXDX
- -61.36 % $ 2.46 M usaUSA
Biocept Biocept
BIOC
- -13.05 % $ 7.29 M usaUSA
Illumina Illumina
ILMN
$ 142.54 -0.49 % $ 22.7 B usaUSA
Oxford Immunotec Global PLC Oxford Immunotec Global PLC
OXFD
- - $ 562 M britainBritain
Interpace Biosciences Interpace Biosciences
IDXG
$ 1.76 -2.22 % $ 7.79 M usaUSA
CareDx, Inc CareDx, Inc
CDNA
$ 19.97 -2.54 % $ 1.06 B usaUSA
Chembio Diagnostics Chembio Diagnostics
CEMI
- 0.22 % $ 16.8 M usaUSA
Check-Cap Ltd. Check-Cap Ltd.
CHEK
- - $ 9.42 M israelIsrael
Lantheus Holdings Lantheus Holdings
LNTH
$ 93.91 -2.86 % $ 6.34 B usaUSA
HTG Molecular Diagnostics HTG Molecular Diagnostics
HTGM
- -20.0 % $ 1.06 M usaUSA
Mettler-Toledo International Mettler-Toledo International
MTD
$ 1 031.64 -0.99 % $ 21.3 B schweizSchweiz
Medpace Holdings Medpace Holdings
MEDP
$ 415.27 -0.93 % $ 12 B usaUSA
Global Cord Blood Corporation Global Cord Blood Corporation
CO
- - $ 399 M chinaChina
NeoGenomics NeoGenomics
NEO
$ 8.24 -1.44 % $ 1.06 B usaUSA
Fluidigm Corporation Fluidigm Corporation
FLDM
- 1.08 % $ 308 M usaUSA
Genetic Technologies Limited Genetic Technologies Limited
GENE
- - $ 7.1 B australiaAustralia
Genetron Holdings Limited Genetron Holdings Limited
GTH
- 0.12 % $ 80.1 M chinaChina
DermTech DermTech
DMTK
- -11.32 % $ 2.94 M usaUSA
National Research Corporation National Research Corporation
NRC
$ 18.62 -1.64 % $ 417 M usaUSA
Charles River Laboratories International Charles River Laboratories International
CRL
$ 150.85 -5.2 % $ 7.48 B usaUSA
PRA Health Sciences, Inc. PRA Health Sciences, Inc.
PRAH
- - $ 10.7 B usaUSA
Natera Natera
NTRA
$ 186.36 -5.36 % $ 18.3 B usaUSA
Enzo Biochem Enzo Biochem
ENZ
- -8.98 % $ 14.8 K usaUSA
Exact Sciences Corporation Exact Sciences Corporation
EXAS
- - $ 19.8 B usaUSA
Koninklijke Philips N.V. Koninklijke Philips N.V.
PHG
$ 25.23 -1.06 % $ 23.9 B niderlandNiderland
Senseonics Holdings Senseonics Holdings
SENS
$ 5.77 -0.86 % $ 241 M usaUSA
Guardant Health Guardant Health
GH
$ 94.92 -3.79 % $ 11.9 B usaUSA
Personalis Personalis
PSNL
$ 6.36 -5.22 % $ 568 M usaUSA
Heska Corporation Heska Corporation
HSKA
- - $ 1.31 B usaUSA
ICON Public Limited Company ICON Public Limited Company
ICLR
$ 116.38 -0.61 % $ 9.6 B irlandaIrlanda
Soleno Therapeutics Soleno Therapeutics
SLNO
$ 53.01 0.04 % $ 2.69 B usaUSA
QIAGEN N.V. QIAGEN N.V.
QGEN
- - $ 10.6 B niderlandNiderland
Biomerica Biomerica
BMRA
$ 2.34 -2.9 % $ 5.38 M usaUSA
Laboratory Corporation of America Holdings Laboratory Corporation of America Holdings
LH
$ 250.4 -1.43 % $ 20.8 B usaUSA
Thermo Fisher Scientific Thermo Fisher Scientific
TMO
$ 438.34 -2.2 % $ 165 B usaUSA
Trinity Biotech plc Trinity Biotech plc
TRIB
$ 0.57 -1.59 % $ 205 M irlandaIrlanda
Celcuity Celcuity
CELC
$ 137.68 2.2 % $ 6.44 B usaUSA
Motus GI Holdings Motus GI Holdings
MOTS
- -34.28 % $ 263 K israelIsrael
Twist Bioscience Corporation Twist Bioscience Corporation
TWST
$ 49.17 -7.14 % $ 2.94 B usaUSA
Waters Corporation Waters Corporation
WAT
$ 329.22 -1.2 % $ 19.6 B usaUSA
Neogen Corporation Neogen Corporation
NEOG
$ 8.19 -2.85 % $ 1.78 B usaUSA
Quest Diagnostics Incorporated Quest Diagnostics Incorporated
DGX
$ 186.61 -0.71 % $ 20.7 B usaUSA